SCHEMBL5401765

SCHEMBL5401765

CN(C)C(=O)c1cc2ccccc2cc1N

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.61
CFTR P13569 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 2/20 0.42
HSD17B10 Q99714 1/20 0.42
MAP4K1 Q92918 3/20 0.41
POLB P06746 1/20 0.40
KEAP1 Q14145 1/20 0.40
GLA P06280 1/20 0.40
HPGD P15428 1/20 0.40
MITF O75030 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
NCOA1 Q15788 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
NCOA3 Q9Y6Q9 1/20 0.40
SLC6A4 P31645 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11800312 0.86 IDO1 (0.58) IDO1CFTRMEN1KMT2AKDM4E
SCHEMBL11794065 0.83 IDO1 (0.54) IDO1CFTRMEN1KMT2AKDM4E
SCHEMBL11686483 0.83 IDO1 (0.59) IDO1KMT2AKDM4EPOLB
SCHEMBL11988856 0.79 IDO1 (0.68) IDO1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL24451031 0.78 IDO1 (0.61) IDO1MEN1KMT2AKDM4EALDH1A1
SCHEMBL24508233 0.77 MEN1 (0.44) IDO1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL11800257 0.77 IDO1 (0.51) IDO1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL30598338 0.76 SMN1; SMN2 (0.55) CFTRMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL538290 0.76 SMN1; SMN2 (0.55) CFTRMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL8006518 0.76 IDO1 (1.00) IDO1MEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7223786-B2 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-29 US disclosed
US-20060111415-A1 2-Aminonaphthalene derivatives and related glycogen phosphorylase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2006-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111415-A1 2-Aminonaphthalene derivatives and related glycogen phosphorylase inhibitors PYGM, GYS1, PYGL IDO1 2919/4885CFTR 4758/4885MEN1 3313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.